Clinical trials: Blood Plasma Therapy
Plasma Cell Myeloma
International Treatment-extension Study in Adult Participants With Multiple Myeloma and Who Have Derived Clinical Benefit From Isatuximab
This is a multi-center, open-label, Phase 2 treatment extension study in participants with multiple myeloma who are still benefitting from isatuximab based therapy following completion of a Phase 1, 2, or 3 parental study.
- Trial name
- NCT05669989
- Testing
- Isatuximab intravenous (IV), Cemiplimab (SAR439684), Dexamethasone
- Where
- 37 sites in United States, Australia and 15 more
- Volunteers
- 70 people
- Sponsor
- Sanofi
Infection, Multiple Myeloma
Antibiotic Therapy in Preventing Early Infection in Patients With Multiple Myeloma Who Are Receiving Chemotherapy
RATIONALE: Giving antibiotics may be effective in preventing or controlling early infection in patients with multiple myeloma and may improve their response to chemotherapy.
- Trial name
- NCT00002850
- Testing
- ciprofloxacin, ofloxacin, 160 mg trimethoprim and 800 mg sulfamethoxazole
- Where
- 45 sites in United States, Peru and 1 more
- Volunteers
- 212 people
- Sponsor
- Gary Morrow
Cancer
Natural History Study of Fungal Infections of the Blood in Patients With Cancer or in Patients Who Have Undergone a Stem Cell Transplant
RATIONALE: Gathering information about how often fungal infections of the blood occur in patients with cancer or in patients who have undergone stem cell transplant may help doctors learn more about the disease.
- Trial name
- NCT00445952
- Testing
- clinical observation, management of therapy complications
- Where
- 5 sites in Belgium, France and 3 more
- Volunteers
- 304 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Obesity, Adiposity
Endoscopic Gastric Mucosal Ablation as a Primary Obesity Therapy
This study is intended to investigate safety and feasibility of a new weight loss technique called endoscopic Gastric Mucosal Ablation (GMA) that does not require surgery, but can be achieved using an endoscopic procedure.
- Trial name
- COMET (NCT05486338)
- Testing
- Hybrid Argon Plasma Coagulation (HAPC)
- Where
- 2 sites in United States
- Volunteers
- 15 people
- Sponsor
- Erbe Elektromedizin GmbH
Androgenetic Alopecia
Activated PRP for Treatment of Androgenetic Alopecia
A clinical trial to assess the effects and safety of PRP activated with pulsed electrical fields (PEFA-PRP) compared with unactivated PRP when used to treat AGA.
- Trial name
- NCT05348343
- Testing
- Autologous platelet-rich plasma
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- Santiste Medical Inc.
Relapsed or Plateau-Phase Multiple Myeloma
Open-Label, Phase 2, Proof of Concept Study in Multiple Myeloma - Denosumab
The purpose of this study is to determine if denosumab is effective in the treatment of relapsed or plateau-phase multiple myeloma.
- Trial name
- NCT00259740
- Testing
- DENOSUMAB
- Volunteers
- 96 people
- Sponsor
- Amgen
Multiple Myeloma and Plasma Cell Neoplasm
Combination Chemo, Peripheral Stem Cell Transplant, Biological Therapy, Pamidronate and Thalidomide for Multiple Myeloma
RATIONALE: Drugs used in chemotherapy work in different ways to stop cancer cells from dividing so they stop growing or die. Peripheral stem cell transplantation may allow doctors to give higher doses of chemotherapy drugs and…
- Trial name
- NCT00004088
- Testing
- filgrastim, recombinant interferon alfa, busulfan
- Where
- 2 sites in United States
- Volunteers
- 77 people
- Sponsor
- City of Hope Medical Center
Chronic Non-healing Skin Ulcers
PRP Versus PRF Versus Conventional Treatment in Chronic Non-healing Skin Ulcers
To compare the therapeutic efficacy of PRP and PRF: two relatively newer modalities in the management of chronic non-healing ulcers versus conventional treatment.
- Trial name
- NCT06281483
- Testing
- platelet-rich plasma, platelet-rich fibrin, Surgical debridement, normal saline washing and dressing coverage
- Where
- Egypt
- Volunteers
- 36 people
- Sponsor
- Kafrelsheikh University
Multiple Myeloma
Frailty Score-guided Dosing of Lenalidomide, Dexamethasone and Daratumumab Induction Therapy
The purpose of this study is to determine if using a subject's baseline frailty score to guide the dosing of lenalidomide in a combination with dexamethasone and daratumumab (DRd lite).
- Trial name
- NCT04223661
- Testing
- Lenalidomide Pill, Dexamethasone, Daratumumab
- Where
- United States
- Sponsor
- Attaya Suvannasankha
Tennis Elbow, PRP
ECRB Tendinopathy: Needling ± PRP After Failure of Rehabilitation
This study evaluates the effect of platelet-rich plasma (PRP) use during needling of the extensor carpalis radialis brevis tendon, after failure of proper reeducation including focal extra-corporal shockwave therapy (ESWT).
- Conditions
- Tennis Elbow, PRP, Tendinopathy, Tendinosis
- Trial name
- NCT03987256
- Testing
- Initial rehabilitation protocol, Needling with PRP, Needling with saline solution
- Where
- Switzerland
- Volunteers
- 58 people
- Sponsor
- Adrien Schwitzguebel
Benign Neoplasms, Vascular Malformations, Brain
Normal Saline Vrs Balanced i.v. Fluids in Neurosurgery
The purpose of this study was to investigate whether the balanced fluids therapy change plasma osmolality in neurosurgical procedures due to brain tumors, meningeomas and arterio-venous malformation.
- Trial name
- NCT03429127
- Testing
- Normal saline, Balanced fluid
- Where
- Croatia
- Volunteers
- 120 people
- Sponsor
- Clinical Hospital Centre Zagreb
Metastatic Gastrointestinal Cancer, Genitourinary Cancer
Next Generation pErsonalized tX(Therapy) With Plasma DNA Trial-2 in Refractory Solid Tumors (The NEXT-2 Trial)
Analysis of cell free DNA(cfDNA), unlike tissue biopsy, presents a new tool for the monitoring and treatment of cancer. The investigators have developed a differentiated sequencing assay, Digital Sequencing Technology (DST) that…
- Trial name
- NCT02140463
- Where
- South Korea
- Volunteers
- 229 people
- Sponsor
- Samsung Medical Center
Septic Shock
PK Analysis of Piperacillin in Septic Shock Patients
Antibiotic dosing in septic shock patients poses a challenge for clinicians due to the pharmacokinetic changes seen in this population.
- Trial name
- NCT02306928
- Testing
- Blood draw
- Where
- Denmark
- Volunteers
- 15 people
- Sponsor
- University of Aarhus
Multiple Myeloma
Phase II Study of Subcutaneous (SC) Bortezomib, Lenalidomide and Dexamethasone for Relapsed and/or Refractory Multiple Myeloma; Followed by SC Bortezomib Maintenance
Background: Bortezomib is a drug approved by the Food and Drug Administration (FDA) to treat patients with multiple myeloma. It is given by intravenous injection. Lenalidomide is a drug that alters the immune system.
- Trial name
- NCT01647165
- Testing
- Bortezomib, Lenalidomide, Dexamethasone
- Sponsor
- National Cancer Institute (NCI)
Waldenstroms Macroglobulinemia
Bortezomib, Dexamethasone, and Rituximab in Untreated Waldenstroms Macroglobulinemia
This is a Phase II multicenter study designed to evaluate the safety and efficacy of combination BDR. BDR will be administered in one 21-day treatment cycle followed by four 35-day treatment cycles to patients with WM.
- Trial name
- BDR-WM (NCT00832234)
- Testing
- Bortezomib, Dexamethasone, Rituximab
- Where
- Greece
- Volunteers
- 59 people
- Sponsor
- European Myeloma Network B.V.
Periodontal Diseases, Gingival Recession Localized Moderate
Hydroxyapetite Nanoparticles and Tricalcium Phosphate Nanoparticles Loaded on Platelet Rich Fibrin Membranes for Treatment of Gingival Recession
The "Glossary of the American of Periodontology" defines gingival recession (GR) as the apical movement of the gingival margin beyond the cement-enamel junction.
- Conditions
- Periodontal Diseases, Gingival Recession Localized Moderate, Nano-hydroxyapatite, Nano Tricalcium Phosphate
- Trial name
- NCT07088809
- Testing
- Nanocrystalline hydroxyapatite loaded in PRF+ coronally advanced flap, Nanocrystalline tricalcium phosphate (NcTCP) loaded in PRF+ coronally advanced flap
- Where
- Egypt
- Volunteers
- 20 people
- Sponsor
- Enas Elgendy
Multiple Myeloma
Novel Combination of Belantamab Mafodotin and Elotuzumab to Enhance Therapeutic Efficacy in Multiple Myeloma
The purpose of this research study is to determine if two drugs approved for treating multiple myeloma, belantamab mafodotin and elotuzumab, are safe and more effective when used together.
- Trial name
- NCT05002816
- Testing
- Elotuzumab, Belantamab mafodotin
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Yale University
Multiple Myeloma
Use of Thalidomide, Lenalidomide, Carfilzomib, Bortezomib and Vorinostat in the Initial Treatment of Newly Diagnosed Multiple Myeloma Patients
The purpose of this study is to compare a standard chemotherapy regimen of cyclophosphamide, dexamethasone plus thalidomide with a newer regimen of cyclophosphamide, dexamethasone plus lenalidomide with or without carfilzomib.
- Trial name
- Myeloma XI (NCT01554852)
- Testing
- Induction (intensive pathway) - cyclophosphamide, lenalidomide, & dexamethasone (CRD) regimen, Induction (intensive pathway) - cyclophosphamide, thalidomide, & dexamethasone (CTD) regimen, Induction (intensive pathway) - carfilzomib, cyclophosphamide, lenalidomide, & dexamethasone (CCRD) regimen
- Where
- United Kingdom
- Volunteers
- 4,420 people
- Sponsor
- University of Leeds
Gonarthrosis
Exercise vs. Topical Diclofenac vs. PRP
Osteoarthritis, the most common type of arthritis, is a chronic and degenerative joint disease. It has been reported to affect more than 300 million adults and elderly individuals worldwide.
- Trial name
- NCT05877027
- Testing
- Exercise, Topical Diclofenac, Platelet-Rich-Plasma (PRP)
- Where
- Turkey (Türkiye)
- Volunteers
- 82 people
- Sponsor
- Istanbul University - Cerrahpasa
Multiple Myeloma, Lymphoma, Non-Hodgkin
AMD3100 (Plerixafor) Given to NHL and MM Patients to Increase the Number of PBSCs When Given a Mobilizing Regimen of G-CSF
This study evaluates the safety and efficacy of plerixafor given in addition to granulocyte-colony stimulating factor (G-CSF) for collection of peripheral blood stem cells (PBSCs) for autologous transplantation in patients with…
- Trial name
- NCT00396266
- Testing
- G-CSF Plus Plerixafor
- Where
- 2 sites in Canada
- Volunteers
- 22 people
- Sponsor
- Genzyme, a Sanofi Company
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.